These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36682262)

  • 1. "The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease".
    Hameiri-Bowen D; Yindom LM; Sovershaeva E; Bandason T; Mayini J; M Rehman A; Simms V; Gift Ngwira L; Flagestad T; Jarl Gutteberg T; McHugh G; Abbas Ferrand R; Rowland-Jones SL
    Int Immunopharmacol; 2023 Mar; 116():109756. PubMed ID: 36682262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial.
    Ferrand RA; McHugh G; Rehman AM; Mujuru H; Simms V; Majonga ED; Nicol MP; Flaegstad T; Gutteberg TJ; Gonzalez-Martinez C; Corbett EL; Rowland-Jones SL; Kranzer K; Weiss HA; Odland JO;
    JAMA Netw Open; 2020 Dec; 3(12):e2028484. PubMed ID: 33331916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial.
    Madanhire T; McHugh G; Simms V; Ngwira L; Gonzalez-Martinez C; Semphere R; Moyo B; Calderwood C; Nicol M; Bandason T; Odland JO; Rehman AM; Ferrand RA
    BMC Pulm Med; 2024 Jul; 24(1):339. PubMed ID: 38997676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial.
    Gonzalez-Martinez C; Kranzer K; McHugh G; Corbett EL; Mujuru H; Nicol MP; Rowland-Jones S; Rehman AM; Gutteberg TJ; Flaegstad T; Odland JO; Ferrand RA;
    Trials; 2017 Dec; 18(1):622. PubMed ID: 29282143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease.
    Abotsi RE; Dube FS; Rehman AM; Claassen-Weitz S; Xia Y; Simms V; Mwaikono KS; Gardner-Lubbe S; McHugh G; Ngwira LG; Kwambana-Adams B; Heyderman RS; Odland JØ; Ferrand RA; Nicol MP;
    Microbiome; 2023 Feb; 11(1):29. PubMed ID: 36803868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection.
    Hameiri-Bowen D; Sovershaeva E; Flaegstad T; Gutteberg TJ; Ngwira LG; Simms V; Rehman AM; Mchugh G; Bandason T; Ferrand RA; Rowland-Jones S; Yindom LM
    AIDS; 2021 Sep; 35(11):1743-1751. PubMed ID: 34074817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease.
    Flygel TT; Hameiri-Bowen D; Simms V; Rowland-Jones S; Ferrand RA; Bandason T; Yindom LM; Odland JØ; Cavanagh JP; Flaegstad T; Sovershaeva E
    HIV Med; 2024 Feb; 25(2):223-232. PubMed ID: 37804064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to additional medication for management of HIV-associated comorbidities among older children and adolescents taking antiretroviral therapy.
    Rehman AM; Simms V; McHugh G; Mujuru H; Ngwira LG; Semphere R; Moyo B; Bandason T; Odland JO; Ferrand RA
    PLoS One; 2022; 17(6):e0269229. PubMed ID: 35704559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease.
    Abotsi RE; Nicol MP; McHugh G; Simms V; Rehman AM; Barthus C; Mbhele S; Moyo BW; Ngwira LG; Mujuru H; Makamure B; Mayini J; Odland JØ; Ferrand RA; Dube FS
    BMC Infect Dis; 2021 Feb; 21(1):216. PubMed ID: 33632144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.
    Hillis GS; Pearson CV; Harding SA; Sutherland S; Ludlam CA; Marioni JC; Prescott RJ; Fox KA; Flapan AD
    Am Heart J; 2004 Jul; 148(1):72-9. PubMed ID: 15215794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants.
    Lowe J; Gillespie D; Hubbard M; Zhang L; Kirby N; Pickles T; Thomas-Jones E; Turner MA; Klein N; Marchesi JR; Hood K; Berrington J; Kotecha S
    BMJ Open; 2020 Oct; 10(10):e041528. PubMed ID: 33028566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lung disease in children and adolescents with HIV: a case-control study.
    McHugh G; Rehman AM; Simms V; Gonzalez-Martinez C; Bandason T; Dauya E; Moyo B; Mujuru H; Rylance J; Sovershaeva E; Weiss HA; Kranzer K; Odland J; Ferrand RA;
    Trop Med Int Health; 2020 May; 25(5):590-599. PubMed ID: 31989731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
    Stick SM; Foti A; Ware RS; Tiddens HAWM; Clements BS; Armstrong DS; Selvadurai H; Tai A; Cooper PJ; Byrnes CA; Belessis Y; Wainwright C; Jaffe A; Robinson P; Saiman L; Sly PD;
    Lancet Respir Med; 2022 Aug; 10(8):776-784. PubMed ID: 35662406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
    Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
    Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection.
    Parchure N; Zouridakis EG; Kaski JC
    Circulation; 2002 Mar; 105(11):1298-303. PubMed ID: 11901039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.
    Chang AB; Grimwood K; Robertson CF; Wilson AC; van Asperen PP; O'Grady KA; Sloots TP; Torzillo PJ; Bailey EJ; McCallum GB; Masters IB; Byrnes CA; Chatfield MD; Buntain HM; Mackay IM; Morris PS
    Trials; 2012 Aug; 13():156. PubMed ID: 22937736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol.
    ABCD study team
    Trials; 2020 Jan; 21(1):71. PubMed ID: 31931848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.